Novartis has received approval in Switzerland for Coartem Baby, the first drug designed specifically to treat malaria in ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children Novartis ( NYSE: NVS) on ...

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

Basel: Novartis has received approval from Swissmedic for Coartem (artemether-lumefantrine) Baby, a first malaria medicine ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

In a historic move, Swissmedic has approved Coartem Baby, the first malaria treatment specifically for newborns and young infants. This cherry-flavore ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...